Senior Manager, Cell Therapy Network Lead Investigator at Bristol-Myers Squibb

Devens, Massachusetts, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, PharmaceuticalsIndustries

Requirements

Bachelor’s degree or equivalent in relevant discipline with a minimum of 5 years of relevant experience. Masters preferred (but not required). Time spent in advanced degree programs may be considered as equivalent relevant experience
Green Belt or Black Belt is preferred but not required
Expert understanding of cGMP regulations and/or business and documentation processes
Expert in root cause analysis, CAPA and risk mitigation
Proficient in project and portfolio management skills

Responsibilities

Serve as lead investigator for global trend investigations and global SAE events
Support site based investigators for complex trend investigations
Manage complex cross-functional projects/programs using project management techniques and tools that is appropriate for the given project
Assemble and lead cross functional matrix teams necessary to close complex trend investigations
Participate in strategic discussions, anticipate bottlenecks, technical risks, and address issues proactively, while fostering an environment of teamwork
Collaborate with SMEs, user groups, quality groups, and other stakeholders to complete complex trend deviations and CAPAs

Skills

Cell Therapy

Trend Investigations

Deviation Management

SAE Investigations

CAPA

Project Management

Cross-Functional Leadership

Quality Assurance

Strategic Planning

Risk Management

Bristol-Myers Squibb

Develops and delivers biopharmaceutical medicines

About Bristol-Myers Squibb

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

New York City, New YorkHeadquarters

1887Year Founded

$33,706.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Risks

Increased competition in oncology from emerging biotech firms like ArsenalBio.

BMS's lawsuit over the 340B Drug Pricing Program may lead to regulatory challenges.

Rapid AI and digital tech evolution may pose integration challenges for BMS.

Differentiation

BMS focuses on innovative cancer treatments through collaborations like ArsenalBio for T cell therapies.

The company emphasizes digital health technologies, enhancing clinical trial management and patient engagement.

BMS offers both innovative and generic medicines, increasing affordable healthcare solutions.

Upsides

BMS's partnership with Medidata enhances clinical research processes and patient outcomes.

The collaboration with AI Proteins advances novel miniprotein-based therapeutics, expanding therapeutic modalities.

BMS's global license agreement with BioArctic expands its portfolio in neurodegenerative diseases.

Land your dream remote job 3x faster with AI

Try Jobo Free